Etripamil: First Approval
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Etripamil (CARDAMYSTTM) is an intranasal L-type calcium channel blocker (CCB) developed by Milestone Pharmaceuticals for the treatment of symptomatic paroxysmal supraventricular tachycardia (PSVT) and is under investigation for atrial fibrillation with rapid ventricular rate (AF-RVR). It received its first approval on the 12 December 2025 in the USA for the conversion of acute symptomatic PSVT episodes to sinus rhythm in adults. Additional global regulatory filings of etripamil for PSVT in adults, a phase II trial of etripamil in pediatrics, and a phase III trial for AF-RVR are in progress. This article summarizes the milestones in the development of etripamil leading to this first approval for PSVT.
More Related Videos
07:26Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3
Published on: August 17, 2011
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
FDA Approved Drugs: Changes to Approved Drugs
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Therapeutic Drug Monitoring: Overview and Classification
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
